Tecarfarin


Armetheon’s late-clinical-stage oral anti-coagulant drug candidate – Tecarfarin – addresses an unmet need – potentially fewer adverse and fatal drug reactions and anticipated compatibility with treatment that includes prosthetic heart valves.

Learn More


Budiodarone


Budiodarone is a clinical-stage oral drug candidate that is being investigated for its potential to suppress ventricular arrhythmias and device firing in patients with implantable cardioverter defibrillators (ICDs). Existing early stage clinical and pre-clinical data suggests that budiodarone may offer dose dependent reduction of life threatening arrhythmias and a potentially lower risk of long term tissue accumulation and related organ toxicities.

Learn More